Joshua Grass
Directeur Général chez Meves Pharmaceuticals, Inc.
Profil
Joshua A.
Grass currently works at Meves Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2018, Escient Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2022, and NFlection Therapeutics, Inc., as Director.
Mr. Grass also formerly worked at Modis Therapeutics, Inc., as President, Chief Executive Officer & Director, Cerus Corp., as Research Scientist, Cowen & Co. LLC, as Principal, BioMarin Pharmaceutical, Inc., as Senior VP-Business & Corporate Development from 2013 to 2016, and Vrolyk & Co., as Associate.
Mr. Grass received his undergraduate degree from California Polytechnic State University (San Luis Obispo) and Masters Business Admin degree from the University of Rochester Simon Business School.
Postes actifs de Joshua Grass
| Sociétés | Poste | Début |
|---|---|---|
Meves Pharmaceuticals, Inc.
 Meves Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Meves Pharmaceuticals, Inc. provides pharmaceutical products and services. The company is headquartered in New York, NY. | Directeur Général | 23/03/2018 |
NFlection Therapeutics, Inc.
 NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Directeur/Membre du Conseil | - |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Directeur Général | 01/12/2021 |
Anciens postes connus de Joshua Grass
| Sociétés | Poste | Fin |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Public Communications Contact | 11/05/2009 |
Modis Therapeutics, Inc.
 Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Directeur Général | - |
Cowen & Co. LLC
 Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Corporate Officer/Principal | - |
| CERUS CORPORATION | Directeur Technique/Scientifique/R&D | - |
| Vrolyk & Co. | Corporate Officer/Principal | - |
Formation de Joshua Grass
| California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| CERUS CORPORATION | Health Technology |
| Entreprise privées | 6 |
|---|---|
| Vrolyk & Co. | |
Cowen & Co. LLC
Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Finance |
Modis Therapeutics, Inc.
Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Commercial Services |
Meves Pharmaceuticals, Inc.
Meves Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Meves Pharmaceuticals, Inc. provides pharmaceutical products and services. The company is headquartered in New York, NY. | Health Technology |
NFlection Therapeutics, Inc.
NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Health Technology |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
